ALS global day 2025: research and clinical advances
Authors:
- Nicola TicozziNTNicola Ticozzi
- on behalf of the Motor Neuron Disease Study Group and the Neurogenetic and Rare Diseases Study Group of the Italian Neurological SocietyOSon behalf of the Motor Neuron Disease Study Group and the Neurogenetic and Rare Diseases Study Group of the Italian Neurological Society
Open Access
- 17 June 2025
- journal article
- editorial
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (8) , 3359-3361
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case seriesThe Lancet, 2025
- The genetics of amyotrophic lateral sclerosisCurrent Opinion in Neurology, 2024
- European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)European Journal of Neurology, 2024
- Fluid biomarkers for amyotrophic lateral sclerosis: a reviewMolecular Neurodegeneration, 2024
- Personalized antisense oligonucleotides ‘for free, for life’ — the n-Lorem FoundationNature Medicine, 2023
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALSNew England Journal of Medicine, 2022
- Amyotrophic lateral sclerosisThe Lancet, 2022
- TRICALS: creating a highway toward a cureAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020
- Secular Trends of Amyotrophic Lateral SclerosisJAMA Neurology, 2017
- The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparisonAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017